Heartland Advisors Inc. Buys Shares of 1,058,311 Core Laboratories Inc. $CLB

Heartland Advisors Inc. purchased a new position in shares of Core Laboratories Inc. (NYSE:CLB) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,058,311 shares of the oil and gas company’s stock, valued at approximately $12,329,000. Heartland Advisors Inc. owned about 2.31% of Core Laboratories as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Core Laboratories in the 2nd quarter valued at $86,910,000. Goldman Sachs Group Inc. increased its position in shares of Core Laboratories by 185.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company’s stock worth $13,549,000 after buying an additional 548,657 shares during the period. Disciplined Growth Investors Inc. MN raised its stake in Core Laboratories by 9.7% during the third quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock worth $73,787,000 after buying an additional 528,976 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Core Laboratories during the second quarter worth $4,675,000. Finally, MAC Alpha Capital Management LP acquired a new position in Core Laboratories in the fourth quarter valued at $5,016,000. Institutional investors and hedge funds own 97.81% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on CLB shares. Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Johnson Rice upgraded Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Thursday, August 13th. Finally, Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Insiders Place Their Bets

In other Core Laboratories news, CEO Lawrence Bruno purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average price of $10.78 per share, with a total value of $53,900.00. Following the transaction, the chief executive officer owned 262,438 shares in the company, valued at $2,829,081.64. The trade was a 1.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.26% of the company’s stock.

Core Laboratories Price Performance

Shares of NYSE:CLB opened at $12.61 on Friday. Core Laboratories Inc. has a twelve month low of $9.79 and a twelve month high of $20.36. The stock’s 50 day moving average is $11.52 and its 200-day moving average is $14.46. The company has a quick ratio of 1.55, a current ratio of 2.12 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $578.55 million, a price-to-earnings ratio of 22.52, a PEG ratio of 2.83 and a beta of 1.03.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The business had revenue of $124.61 million during the quarter, compared to analyst estimates of $126.26 million. During the same quarter in the previous year, the business posted $0.19 EPS. Core Laboratories’s quarterly revenue was down 4.3% on a year-over-year basis. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Sell-side analysts forecast that Core Laboratories Inc. will post 0.56 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Monday, August 10th will be issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, August 10th. Core Laboratories’s dividend payout ratio is currently 7.14%.

Core Laboratories Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.